Democratizing DNA: Inside George Church's Drive to Decode the Human Genome

For decades, academic research and commercial biotechnology have intersected inside the laboratory of George Church. As a professor of genetics at Harvard Medical School and an investigator across several Boston-area institutions, Church has directed his attention toward turning laboratory sequencing tools into practical applications. In 2014, that ambition led to the creation of Veritas Genetics, a firm structured around delivering comprehensive genetic data directly to individuals.

Lowering the Barriers to Whole-Genome Sequencing

Veritas Genetics was established in Danvers, Massachusetts, by Church alongside co-founders Mirza Cifric, Preston Estep, and Jonathan Zhao. The company set out to provide the general population with the advantages of genomic analysis by substantially reducing testing expenses. It stood among the earliest enterprises to present complete genome sequencing and data interpretation for less than one thousand dollars. By 2018, the venture unveiled its central offering, known as myGenome. This product analyzed whole-genome sequencing results to outline personal risks tied to cancer, cardiovascular conditions, carrier indicators, and medication reactions. Veritas captured broad media coverage by introducing a promotional pricing tier of 199 dollars per order, an amount well below standard commercial rates at that stage. The business expanded internationally through Veritas Intercontinental, reaching markets in Europe and Latin America, and gained spots on the CNBC Disruptor 50 list in both 2018 and 2019. Following an exploration of strategic alternatives in late 2019, Veritas secured additional capital in January 2020 to continue domestic operations before being acquired by the digital health firm LetsGetChecked in March 2022.

From Molecular Foundations to Sequencing Inventions

The business initiatives that Church helped launch stem from foundational academic work dating to the early 1980s. After completing an undergraduate program in chemistry and zoology at Duke University, he pursued doctoral research at Harvard University under Walter Gilbert, focusing on mobile genetic elements within introns. In 1984, Church and Gilbert detailed the first direct genomic sequencing methodology, creating an imaging and fluid-based process that bypassed bacterial cloning and anticipated current sequencing systems. That same year, Church also assisted in launching the Human Genome Project. Subsequent work from his Harvard laboratory broadened the scope of sequencing tools. Church devised barcode tags and molecular multiplexing, and in 1995 he co-invented nanopore sequencing techniques. Early commercialization emerged when software and automated sequencing protocols from his laboratory transitioned to Genome Therapeutics Corporation, enabling the initial sequencing of a bacterial genome, Helicobacter pylori, in 1994. Across his academic tenure, Church has been involved in launching roughly fifty biotechnology firms, with sixteen ventures emerging from his Harvard team in 2018 alone.

Open Data and Expanding Biotech Ventures

In parallel with commercial developments, Church has consistently emphasized broad public access to genetic material. He became the fifth individual to have his complete genome sequenced and was the first person to openly publish his medical records and DNA profiles for scientific study. In 2005, he established the Personal Genome Project to assemble public-access datasets covering both traits and human sequence information, samples of which serve as standards for federal evaluation programs. This interest in open information guided subsequent corporate ventures. Beyond Veritas Genetics, Church co-founded Nebula Genomics in 2018 to pair whole-genome sequencing with distributed data security, and in 2021 he co-founded HLTH.network to construct a data-sharing marketplace. In 2025, he joined the AI agent platform Lila Sciences as chief scientist. His laboratory endeavors have also spanned genome engineering with CRISPR and synthetic biology, creating enterprise spinouts including Colossal Biosciences to work on woolly mammoth revival and Rejuvenate Bio to investigate therapeutic interventions for aging.